KALEIDO BIOSCIENCES, INC.

(KLDO)
  Report
Delayed OTC Markets  -  05/23 03:55:29 pm EDT
0.0561 USD   +4.86%
04/20KALEIDO BIOSCIENCES, INC.(NASDAQGS : KLDO) dropped from S&P Global BMI Index
CI
04/20KALEIDO BIOSCIENCES, INC.(NASDAQGS : KLDO) dropped from S&P TMI Index
CI
04/15KALEIDO BIOSCIENCES, INC.(NASDAQGS : KLDO) dropped from NASDAQ Composite Index
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Kaleido Biosciences Announces Expansion of Collaboration with Janssen to Explore Potential of Microbiome Metabolic Therapies to Prevent Childhood-Onset of Atopic, Immune and Metabolic Conditions

12/06/2021 | 07:30am EDT

Kaleido Biosciences, Inc. announced the extension and expansion of its research collaboration with Janssen Biotech, Inc. The collaboration is designed to explore the potential for Microbiome Metabolic Therapies (MMT?) to prevent childhood-onset of atopic, immune and metabolic conditions by promoting healthy function of the gut microbiome. Since the beginning of the collaboration, Kaleido?s proprietary ex vivo screening platform has identified several potential MMTs that support the growth of specific beneficial microbes in the gut microbiome believed to be associated with the development of infant immune systems. Given this progress, the existing agreement with Janssen has subsequently been extended and expanded to optimize the identified MMTs for their ability to support growth of these advantageous microbes and their metabolites. Janssen will fund the additional costs associated with the expanded scope of the collaboration.


© S&P Capital IQ 2021
All news about KALEIDO BIOSCIENCES, INC.
04/20KALEIDO BIOSCIENCES, INC.(NASDAQGS : KLDO) dropped from S&P Global BMI Index
CI
04/20KALEIDO BIOSCIENCES, INC.(NASDAQGS : KLDO) dropped from S&P TMI Index
CI
04/15KALEIDO BIOSCIENCES, INC.(NASDAQGS : KLDO) dropped from NASDAQ Composite Index
CI
04/14Top Premarket Gainers
MT
04/14CAPITALGAINSREPORT : Must See Healthcare Stocks Under $1 (WHSI, KLDO, AGRX, PTE, AKBA)
AQ
04/13Top Premarket Gainers
MT
04/08Top Midday Decliners
MT
04/08Kaleido Biosciences Ceases Operations, Will Delist From Nasdaq; Shares Fall
MT
04/08KALEIDO BIOSCIENCES, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing ..
AQ
04/08Kaleido Biosciences, Inc. Announces Management Changes
CI
More news
Analyst Recommendations on KALEIDO BIOSCIENCES, INC.
More recommendations
Financials (USD)
Sales
Net income
Net Debt
P/E ratio
Yield
Capitalization 2,28 M 2,28 M -
EV / Sales -1
EV / Sales 0
Nbr of Employees 76
Free-Float 95,0%
Chart KALEIDO BIOSCIENCES, INC.
Duration : Period :
Kaleido Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KALEIDO BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Mean consensus -
Number of Analysts 0
Last Close Price 0,05
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Theo Melas-Kyriazi Chairman
Kimberly Hocknell Senior Vice President-Technical Operations
Alison Long Chief Medical Officer
Mark Wingertzahn Head-Development, SVP-Research & Development
Bonnie L. Bassler Independent Director
Sector and Competitors
1st jan.Capi. (M$)
KALEIDO BIOSCIENCES, INC.-97.76%2
MODERNA, INC.-46.35%54 195
LONZA GROUP AG-27.84%41 796
IQVIA HOLDINGS INC.-28.46%38 202
SEAGEN INC.-9.68%25 704
ICON PUBLIC LIMITED COMPANY-30.22%17 567